Please enable JavaScript.

Coggle requires JavaScript to display documents.

Gástrico/esófago - Coggle Diagram

- - - - QT perioperatoria
        
        FLOT 4c y 4c: SLR 30m, SG 50m
        
        PF 2-3c y 2-3c: SG 5a 38%
    - - QTRT
        
        Indicación: <D2
        
        5FU/Capecitabina pre-concomitante-post: SLR 27m, SG 35m
      - QT
        
        Indicación: D2
        
        XELOX 6m: SLR 68%, SG 78%
        
        PF
  - - - Cisplatino 5FU/capecitabina trastuzumab: TRO 51%, SLP 6.7m, SG 13.8m
      - Pembrolizumab: CPS>1 SLP 2m NS, SG 10.6m NS, CPS>10 SLP 2.9m NS, SG 17.4m NS
      - Cisplatino 5FU/capecitabina pembrolizumab: CPS>1 SLP 6.9m NS, SG 11.1m NS, CPS>10 SG 12.3m NS
      - XELOX/FOLFOX nivolumab: CPS>5, TRO 60%, SLP 7.7m, SG 14.4m
    - - Paclitaxel semanal ramucirumab: SG 9.6m
      - Ramucirumab: SG 5.2m
      - Paclitaxel semanal: SG 7.4m
    - - TAS 102
  - - - QTRT
        
        Carboplatino paclitaxel 5c: RPC 28%, SLR 37.7m, SG 48.6m
        
        PF 2c: SG 5a 39%
        
        FOLFOX 3c y 3c después: SG 20.3m NS
      - QT
        
        PF 2c: SG 23.4m
      - QT perioperatoria
        
        Solo UGE, como neoadyuvancia de gástrico
    - - 5FU/Capecitabina pre-concomitante-post: SLR 27m, SG 35m
      - XELOX 6m: SLR 68%, SG 78%
      - Nivolumab 1a (residual post neo): SLE 22.4m